Key result
Pulmonary vasodilators and statins show promise in COPD patients with moderate-to-severe pulmonary hypertension.
Why the study?
Do pulmonary vasodilators and statins improve outcomes in patients with pulmonary hypertension secondary to COPD?
Population
Patients with pulmonary hypertension secondary to chronic obstructive pulmonary disease (COPD)
Design
Review
Authors
Loading...
May support targeted therapy in select moderate-severe COPD-PH; leaves open confirmation by prospective RCTs.
Do pulmonary vasodilators and statins improve outcomes in patients with pulmonary hypertension secondary to COPD?
This review highlights the potential role of targeted pulmonary vasodilator therapy and statins in a specific subset of COPD patients with moderate to severe pulmonary hypertension.
Shujaat et al. (2012) conducted a review in Pulmonary Hypertension Secondary to COPD. Pulmonary vasodilators and statins was evaluated. Pulmonary vasodilators and statins show promise for treating pulmonary hypertension secondary to COPD in patients with moderate to severe PH (mPAP > 25 mm Hg) without severe hyperinflation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: